3:57 PM
 | 
May 14, 2018
 |  BC Extra  |  Politics & Policy

FDA to hold public meeting on chronic pain therapy

FDA will hold a public meeting July 9 to discuss drug development for chronic pain. Topics include the symptoms and daily affect of chronic pain on patients and patients' perspectives on current treatment.

FDA Commissioner Scott Gottlieb said in a blog post the meeting will allow patients to express their views on chronic pain treatment and challenges to accessing therapy.

He added that as FDA learns about how chronic pain is managed, the agency can "balance between policies that allow appropriate prescribing for those in true need of these medicines and preventing unnecessary exposure to opioids that can increase the rate of new addiction."

FDA plans to establish new guidance documents outlining an "efficient, modern pathway" for developing pain candidates "to modernize FDA's current guidance on analgesic drugs, to promote more new drug innovation." FDA has not yet released a timeline for the guidance.

As part of an effort to address the opioid abuse epidemic, FDA released draft guidance in April for the development and clinical trial design of sustained-release depot buprenorphine products (see BioCentury Extra, April 20).

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD